Compare CVKD & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVKD | GOVX |
|---|---|---|
| Founded | 2022 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.0M |
| IPO Year | 2022 | 1996 |
| Metric | CVKD | GOVX |
|---|---|---|
| Price | $1.71 | $1.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $14.00 | ★ $240.00 |
| AVG Volume (30 Days) | 103.3K | ★ 286.6K |
| Earning Date | 11-16-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.94 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,489,145.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.82 | $0.11 |
| 52 Week High | $12.50 | $1,002.75 |
| Indicator | CVKD | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 66.44 | 55.16 |
| Support Level | $0.88 | $0.11 |
| Resistance Level | $2.23 | $3.00 |
| Average True Range (ATR) | 0.21 | 0.31 |
| MACD | 0.07 | 0.30 |
| Stochastic Oscillator | 78.44 | 62.62 |
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.